Novo Holdings and Vivo Capital lead USD200m Series A investment in Esco Lifesciences Group
Novo Holdings has co-led with Vivo Capital the over-subscribed USD200 million Series A and Crossover round in Esco Lifesciences Group (Esco), a leading provider of life sciences tools and services.